Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer: A Systematic Review
Autor: | Alexander G. Heriot, Wei Mou Lim, Kasmira Wilson, Vignesh Narasimhan, Michael Michael, Robert G. Ramsay, Michael Flood |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
medicine.medical_specialty Colorectal cancer business.industry Rectal Neoplasms MEDLINE Cancer Cochrane Library medicine.disease Precision medicine Article Organoids Internal medicine Colonic Neoplasms medicine Humans Surgery Hyperthermic intraperitoneal chemotherapy Personalized medicine Prospective Studies Precision Medicine business Chemoradiotherapy |
Zdroj: | Ann Surg Oncol |
ISSN: | 1534-4681 |
Popis: | Patients with locally advanced or metastatic colorectal cancer (CRC) display heterogeneous responses to standard-of-care therapy. Robust preclinical models of malignancy in the form of patient-derived tumor organoids (PDTOs) have recently come to the fore in tailoring patient care to a personalized medicine level. This study aimed to review the literature systematically regarding PTDOs and gauge their impact on precision medicine in the management of CRC. A PRISMA-compliant systematic review of the MEDLINE, EMBASE, Web of Science, and Cochrane Library databases was performed. The results were categorized based on the primary objective of the individual studies as follows: organoid use in predicting effective hyperthermic intraperitoneal chemotherapy (HIPEC), systemic chemotherapy in CRC, or neoadjuvant chemoradiotherapy in rectal cancer. The literature search found 200 publications, 16 of which met the inclusion criteria. Organoid models of primary and metastatic CRC have been increasingly used to assess clinical responses to standard therapy. Marked heterogeneity exists, matching the responses observed in clinical practice with ex vivo drug and radiation screening. Repeated correlation between organoid and patient sensitivity to forms of HIPEC, systemic chemotherapy, and chemoradiotherapy has been observed. Patient-derived tumor organoids are the latest tool in predictive translational research. Current organoid-based studies in precision medicine have shown their great potential for predicting the clinical response of patients to CRC therapy. Larger-scale, prospective data are required to fully support this exciting avenue in cancer care. |
Databáze: | OpenAIRE |
Externí odkaz: |